Search the database for deliberate release of GM medicinal products
| EU record number |
Title |
Company / Sponsor |
Treated organism |
Genetic modification |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults. |
Institut Pasteur - Paris |
Humans |
Gag, Pol, Nef genes of HIV |
| B/BE/07/BVW3 |
A multi-centre phase I study to evaluate the safety and tolerability of a heterologous prime-boost vaccination with INX102-3697 HBV pDNA/INX102-0557 HBV MVA in healthy volunteers and HBeAg+ chronic hepatitis patients |
GENimmune N.V. |
Humans |
Hepatitis B virus polyepitope gene |
| B/BE/07/BVW1 |
Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis |
ActoGeniX N.V. |
Humans |
Gene coding for the human interleukin-10 (hIL-10) |
| B/BE/03/B3 |
Phase I multicentre study of TG1024 (Adenovirus interleukin 2) in patients with metastatic melanoma or other advanced solid tumor cancers |
Transgene S.A. |
Humans |
gene coding for human interleukin 2 |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A phase 1 randomized, placebo-controlled, double-blind, dose escalation trial to evaluate the safety and immunogenicity of tgAAC09, a gag-PR-DRT AAV HIV vaccine |
International AIDS Vaccine Initiative (IAVI) |
Humans |
genes for the gag, protease and part of the reverse transcriptase proteins of HIV-1 |
